What's New

Foundation Announces Recipients of the 2014 Merit Awards in Genitourinary Cancers

For Immediate Release:
December 5, 2013
Kate Blackburn
Phone: (571) 483-1379
kate.blackburn@asco.org

ALEXANDRIA, Va. – The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) today announced the recipients of its 2014 Conquer Cancer Foundation of ASCO Merit Awards in Genitourinary Cancers, which recognize rising oncology researchers for their contributions to the field.  The recipients will be recognized at the 2014 Genitourinary Cancers Symposium taking place January 30 – February 1 in San Francisco, CA.

“Young investigators, like those receiving this year’s Merit Awards, are the future of oncology.  The Foundation recognizes their dedication to advancing the care of patients living with cancer and values their efforts toward creating a world free from the fear of cancer”

-W. Charles Penley, MD, FASCO


“Young investigators, like those receiving this year’s Merit Awards, are the future of oncology,” said W. Charles Penley, MD, FASCO, Chair of the Conquer Cancer Foundation Board of Directors. “The Conquer Cancer Foundation recognizes their dedication to advancing the care of patients living with cancer and values their efforts toward creating a world free from the fear of cancer.”

This year’s Symposium will feature research advances on the treatment and management of a variety of genitourinary cancers, including cancers of the bladder, kidneys, penis, prostate, testis and urethra. The Conquer Cancer Foundation of ASCO Merit Awards are designed to promote clinical cancer research in these areas by providing the opportunity for recipients to present their findings at the Symposium.

The 2014 Merit Award in Genitourinary Cancers recipients and their abstracts are:

  • Arun Azad, MBBS, FRACP, PhD, British Columbia Cancer Agency
    Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    (Abstract 29)

  • Alejandro Berlin, MD, Princess Margaret Cancer Centre/University Health Network, University of Toronto
    Using ΝΒΝ to predict biochemical relapse following image-guided radiotherapy for intermediate-risk prostate cancer.
    (Abstract 26)

  • Mauricio Burotto Pichun, MD, National Cancer Institute, National Institutes of Health
    Phase II clinical trial of bevacizumab plus ixabepilone in renal cell carcinoma.
    (Abstract 427)

  • Heather Cheng, MD, PhD, University of Washington
    The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC
    .
    (Abstract 18)

  • David Chism, MD, MS, UNC Lineberger Comprehensive Cancer Center
    BASE47 gene set predictor as an identifier of “basal-like” subtype of urothelial carcinoma of the bladder in African Americans
    .
    (Abstract 300)

  • André Fay, MD, Dana-Farber Cancer Institute
    PD-L1 expression in non-clear cell renal cell carcinoma
    .
    (Abstract 424)

  • Phillip Gray, MD, Harvard Radiation Oncology Program
    Modern patterns of care in testicular seminoma: Results from the National Cancer database.
    (Abstract 368)

  • Abraham Hakimi, MD, Memorial Sloan-Kettering Cancer Center
    Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma
    .
    (Abstract 395)

  • Jenny Ko, MD, British Columbia Cancer Agency
    The international metastatic renal cell carcinoma database consortium model as a prognostic tool in metastatic renal cell carcinoma patients previously treated with first-line targeted therapy
    .
    (Abstract 398)

  • Raya Leibowitz-Amit, MD, PhD, Princess Margaret Cancer Centre, University Health Network, University of Toronto
    A single-arm, phase II, multicenter trial of sunitinib maleate in locally advanced or metastatic pheochromocytoma/paraganglioma: Interim results.
    (Abstract 431)

  • Amitkumar Mehta, MD, University of Alabama at Birmingham
    Comprehensive kinase profiling to classify clear cell-renal cell carcinoma.
    (Abstract 409)

  • Christos Mikropoulos, MD, The Royal Marsden Hospital
    The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.
    (Abstract 22)

  • Matthew Mossanen, MD, University of Washington School of Medicine
    Prevalence and adverse impact of extended antibiotic prophylaxis in urologic oncology surgery.
    (Abstract 294)

  • Matteo Santoni, MD, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria
    Differences in terms of progression-free survival and overall survival in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
    (Abstract 421)

  • Francisco Vera-Badillo, MD, Princess Margaret Cancer Centre, University Health Network, University of Toronto
    Response to systemic therapy in non-clear cell renal cell carcinomas: A systematic review and meta-analysis.
    (Abstract 425)

The Conquer Cancer Foundation celebrated the 30th anniversary of its Grants and Awards Program this year. Learn more about this milestone and how you can join the Foundation’s efforts to support the next 30 years at  www.conquercancerfoundation.org.

The 2014 Genitourinary Cancers Symposium Merit Awards are supported by: the Conquer Cancer Foundation Mission Endowment; Lilly; Millennium: The Takeda Oncology Company; and Shine for Scott, Inc.